NCT00112502View on ClinicalTrials.gov

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Brain and Central Nervous System TumorsGlioblastoma Multiforme
Interventions
DRUG

Celecoxib

400 mg orally twice a day continuous dosing

DRUG

Isotretinoin

40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.

DRUG

Temozolomide

150 mg/m2 orally daily, 7 days on treatment, 7 days off.

DRUG

Thalidomide

400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)

Trial Locations (12)

29303

CCOP - Upstate Carolina, Spartanburg

49503

CCOP - Grand Rapids, Grand Rapids

62526

CCOP - Central Illinois, Decatur

64131

CCOP - Kansas City, Kansas City

65804

Cancer Research for the Ozarks, Springfield

72913

Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith

32806-2134

University of Texas MD Anderson Cancer Center at Orlando, Orlando

30342-1701

CCOP - Atlanta Regional, Atlanta

67214-3882

CCOP - Wichita, Wichita

49007-3731

CCOP - Kalamazoo, Kalamazoo

43210-1240

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus

77030-4009

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter